Published on November 23, 2009 at 9:06 AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."
The GASTRO 2009 meeting is a joint world conference in the area of gastroenterology. This meeting will bring together the world's leading organizations - the United European Gastroenterology Federation (UEGF), World Gastroenterology Organization (WGO), World Organization of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG) - for one of the biggest congresses in this area of medicine with more than 12,000 scientists from around the world expected to attend.
SOURCE Lexicon Pharmaceuticals, Inc.
327ecc42-217b-4076-ba3f-76d6146c6537|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Autoimmune Disease, Biomarker, Constipation, Diabetes, Diarrhea, Endoscopy, Gastroenterology, Glaucoma, Irritable Bowel Syndrome, Serotonin, Tryptophan